Nectar Lifesciences share news, announcements and annual reports
NSE: NECLIFEBSE: 532649Pharmaceuticals & BiotechnologySmall Cap
Nectar Lifesciences Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jul 2005
Last close ₹10.33down ₹0.01 (0.10%)BSE ₹10.31
Share price at the NSE close on 29 Oct 2026. Previous close ₹10.34.
29 Oct: open ₹10.36, high ₹10.49, low ₹10.20
52-week range of traded prices to 29 Oct 2026
₹9.30Low, 30 Mar 2026₹22.40High, 23 Dec 2025
- Under NSE's long-term additional surveillance, stage I, on the list for 29 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹201 Cr2,221st largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 0.34
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- −31.9%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹171 crore of one-off items, the largest of them in the quarter to Sep 2025.
- −9.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- −15.4%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 44,04072.5% delivered
Nectar Lifesciences shareholder meetings
73 filed, newest first. Page 1 of 2.
Oct 2026
Sep 2026
18 Sep · Meeting
Aug 2026
Mar 2026
13 Mar · Meeting
Jan 2026
28 Jan · Meeting
Oct 2025
Sep 2025
29 Sep · Meeting
Aug 2025
Jul 2025
Sep 2024
Sep 2023
Nov 2022
17 Nov · Meeting
Sep 2022
21 Sep · Meeting
Sep 2021
21 Sep · Meeting
Feb 2021
Jan 2021
Sep 2020
Sep 2019
Aug 2019
Aug 2018
Sep 2017
28 Sep · Meeting
Aug 2017
Sep 2016
Aug 2016
Oct 2015
Aug 2015
Dec 2014
Nov 2014
Oct 2014
Sep 2014
30 Sep · Meeting
Members in their Annual General Meeting held on September 30, 2014 have declared the Final Dividend of Re. 0.10/- per equity share ( 10% on the face value of Re.1/- per equity share) for the financial year 2013-14. The Dividend will be paid latest by October 28, 2014.
Aug 2014
11 Aug · Meeting
Company has fixed Book Closure from August 23, 2014 to August 31, 2014 (both days inclusive) for the purpose of Annual General Meeting scheduled to be held on September 30, 2014 and Dividend, if any.
Oct 2013
Sep 2013
30 Sep · Meeting
Proceedings of Annual General Meeting held on September 30, 2013: 1. Adoption of Audited Financial statements for the year 2012-13 together with Directors and Auditors Reports thereon. 2. Declaration of Final Dividend @ 10% i.e. Re. 0.10/- per Equity Share. 3. Re-appointment of Mr. Vijay J. Shah as Director after retirement by rotation. 4. Re-appointment of Mr. Ajay Swaroop as Director after retirement by rotation. 5. Re-appointment M/s Datta Singla & Company, Chartered Accountants as Statutory Auditors of the Company. 6. Appointment of Mr. H.P. Singh as Director of the company. 7. Appointment of Mr. H.P.Singh as Director & President (Operations) and fix his remuneration.
Aug 2013
13 Aug · Meeting
Company has fixed Book Closure from September 21, 2013 to September 30, 2013 for the purpose of Annual General Meeting scheduled to be held on September 30, 2013 & Dividend.